BR112018011131A2 - terapia de combinação baseada em inibidores de sinal de pd-1 - Google Patents

terapia de combinação baseada em inibidores de sinal de pd-1

Info

Publication number
BR112018011131A2
BR112018011131A2 BR112018011131-7A BR112018011131A BR112018011131A2 BR 112018011131 A2 BR112018011131 A2 BR 112018011131A2 BR 112018011131 A BR112018011131 A BR 112018011131A BR 112018011131 A2 BR112018011131 A2 BR 112018011131A2
Authority
BR
Brazil
Prior art keywords
substances
signal inhibitor
combined therapy
iii
signals downstream
Prior art date
Application number
BR112018011131-7A
Other languages
English (en)
Japanese (ja)
Inventor
Honjo Tasuku
Chamoto Kenji
Fagarasan Sidonia
Original Assignee
Kyoto University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University filed Critical Kyoto University
Publication of BR112018011131A2 publication Critical patent/BR112018011131A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a uma nova estratégia de tratamento para tratamento com anticorpo anti-pd-1. uma composição farmacêutica incluindo pelo menos uma substância selecionada do grupo que consiste em (i) a (iii) abaixo, administrada antes, depois ou simultaneamente com a administração de um inibidor de sinal de pd-1: (i) geradores de ros e substâncias que controlam os sinais a jusante dos mesmos; (ii) substâncias que exibem um efeito de desacoplamento e substâncias que controlam os sinais a jusante dos mesmos; e (iii) aminoácidos.
BR112018011131-7A 2015-12-07 2016-12-05 terapia de combinação baseada em inibidores de sinal de pd-1 BR112018011131A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2015238511 2015-12-07
JP2015-238511 2015-12-07
JP2016119695 2016-06-16
JP2016-119695 2016-06-16
PCT/JP2016/086045 WO2017099034A1 (ja) 2015-12-07 2016-12-05 Ｐｄ－１シグナル阻害剤の併用療法

Publications (1)

Publication Number Publication Date
BR112018011131A2 true BR112018011131A2 (pt) 2018-11-21

Family

ID=59014100

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011131-7A BR112018011131A2 (pt) 2015-12-07 2016-12-05 terapia de combinação baseada em inibidores de sinal de pd-1

Country Status (13)

Country Link
US (3) US20180362650A1 (pt)
EP (2) EP4218819A3 (pt)
JP (1) JP6994240B2 (pt)
KR (1) KR20180093990A (pt)
CN (3) CN108601840A (pt)
AU (1) AU2016366250A1 (pt)
BR (1) BR112018011131A2 (pt)
CA (1) CA3007613A1 (pt)
IL (1) IL259857A (pt)
MX (1) MX2018006518A (pt)
SG (2) SG11201804473RA (pt)
TW (1) TW201726169A (pt)
WO (1) WO2017099034A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222949A1 (en) 2017-06-01 2018-12-06 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
AU2018302656A1 (en) * 2017-07-20 2020-01-16 Fuso Pharmaceutical Industries,Ltd. Combination use of inhibitor targeting PD-1/PD-L1 and COX-2 inhibitor
CN118084940A (zh) 2018-02-13 2024-05-28 吉利德科学公司 Pd-1/pd-l1抑制剂
JPWO2019187673A1 (ja) * 2018-03-29 2021-04-08 ソニー株式会社 情報処理装置、情報処理方法及びプログラム
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CR20210013A (es) 2018-07-13 2021-02-26 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
CA3117199C (en) 2018-10-24 2024-03-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
JP7574195B2 (ja) * 2019-01-04 2024-10-28 ジェネクスト テクノロジーズ インコーポレイテッド 生体内ラジカル線量測定及び生体内ヒドロキシルラジカルのタンパク質フットプリント法
WO2020169707A1 (en) * 2019-02-21 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Foxo1 inhibitor for use in the treatment of latent virus infection
RU2731293C1 (ru) 2019-04-12 2020-09-01 Игорь Петрович Белецкий Способ получения генно-модифицированных линий клеток натуральных киллеров с нокаутированным геном PD-1 и повышенной экспрессией белков семейства Фактора Некроза Опухолей для иммунотерапии онкологических заболеваний
CN114728068A (zh) * 2019-11-13 2022-07-08 国立大学法人京都大学 Pd-1信号抑制剂的联合疗法
US20220062390A1 (en) 2020-08-26 2022-03-03 Dr. Reddy's Laboratories Sa Methods of treating cancer
CN112472710A (zh) * 2020-11-05 2021-03-12 中国人民解放军海军军医大学 烟酰胺腺嘌呤二核苷酸前体在制备免疫检查点抑制剂抗肿瘤增敏药物中的应用
WO2022197554A1 (en) * 2021-03-16 2022-09-22 University Of Massachusetts Photocaged citrulline analogs and methods for site-specific incorporation of citrulline into proteins
CN113069529A (zh) * 2021-04-16 2021-07-06 郑州大学第一附属医院 Gsh联合pd-1/pd-l1阻断剂用于促进cd8+t细胞功能的用途
WO2023076880A1 (en) * 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
CN115414343B (zh) * 2022-09-29 2023-11-21 中南大学湘雅医院 α-酮戊二酸及其衍生物的应用、防治皮肤肿瘤的药物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383224C (en) 1999-09-21 2010-12-07 Geetha Ghai Extracts of orange peel for prevention and treatment of cancer
KR20030067935A (ko) 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
US20150329617A1 (en) * 2001-03-14 2015-11-19 Dynal Biotech Asa Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
EP1582207A4 (en) 2002-12-26 2008-03-05 Ajinomoto Kk HEMMER FOR OUTBREAKING AND PROGREDIENCE OF LIVER CANCER
JP5248747B2 (ja) 2006-01-19 2013-07-31 キッセイ薬品工業株式会社 アディポネクチン受容体発現賦活薬
JP6041333B2 (ja) 2011-01-13 2016-12-07 学校法人近畿大学 抗腫瘍剤
CN104603133B (zh) 2012-07-10 2016-11-02 巴斯利尔药物股份公司 用于治疗癌症和免疫抑制的组合疗法
ES2813340T3 (es) * 2012-09-21 2021-03-23 Intensity Therapeutics Inc Método de tratamiento del cáncer
LT3083686T (lt) 2013-12-17 2020-01-10 F. Hoffmann-La Roche Ag Vėžinių ligų gydymo būdai naudojant pd-1 ašies rišimosi antagonistus ir taksanus
JP6104417B2 (ja) 2016-02-02 2017-03-29 キヤノン株式会社 制御装置、制御方法、及びプログラム

Also Published As

Publication number Publication date
CN108601840A (zh) 2018-09-28
EP3388084A1 (en) 2018-10-17
TW201726169A (zh) 2017-08-01
US20180362650A1 (en) 2018-12-20
AU2016366250A1 (en) 2018-06-14
CA3007613A1 (en) 2017-06-15
KR20180093990A (ko) 2018-08-22
JP6994240B2 (ja) 2022-02-04
WO2017099034A1 (ja) 2017-06-15
CN114601930A (zh) 2022-06-10
SG10202006032VA (en) 2020-07-29
EP4218819A2 (en) 2023-08-02
US20230272077A1 (en) 2023-08-31
SG11201804473RA (en) 2018-06-28
IL259857A (en) 2018-07-31
EP4218819A3 (en) 2023-08-23
CN114404595A (zh) 2022-04-29
US20230265193A1 (en) 2023-08-24
MX2018006518A (es) 2019-01-10
JPWO2017099034A1 (ja) 2018-11-01
EP3388084A4 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
BR112018011131A2 (pt) terapia de combinação baseada em inibidores de sinal de pd-1
CL2023002682A1 (es) Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos
BR112018008918A2 (pt) compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
BR112019001794A2 (pt) composição de cannabis
BR112017014067A2 (pt) composição para tratar doenças relacionadas a il-6
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
BR112015014372A2 (pt) inibidores de autotaxina
BR112017005393A2 (pt) composto de fórmula i, método de preparação de um conjugado de fórmula a, conjugado de fórmula a1, composição compreendendo uma mistura dos compostos de conjugado de anticorpo-fármaco, composição farmacêutica, e uso de um conjugado ou de uma composição
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
BR112015030385A2 (pt) inibidores de pi3 delta e gama quinase seletivos duplos
BR112018069601A2 (pt) derivados de indolina substituídos como inibidores da replicação viral da dengue
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112014012607A2 (pt) métodos de tratamento usando um inibidor de interferon gama
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
BR112017018328A2 (pt) anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
BR112022009631A2 (pt) Combinações de inibidores de dgk e antagonistas do ponto de checagem
BR112016026518A2 (pt) Ácidos hidroxâmicos heterocíclicos como inibidores da proteína desacetilase e inibidores duais de proteína desacetilase-proteína cinase e métodos de uso dos mesmos
BR112015022092A2 (pt) derivado de di-hidropiridazina-3,5-diona
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015000808A2 (pt) regime de dosagem para inibidores de janus quinase (jak)
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
BR112017022846A2 (pt) combinação de dose fixa inviolável que proporciona rápida liberação de dois fármacos de partículas diferentes

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2699 DE 27-09-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.